Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a post hoc analysis of a phase III trial

OBJECTIVE: This post hoc analysis of the phase III Active PSoriaTic Arthritis RAndomizEd TriAl (ASTRAEA) evaluated the effect of baseline body mass index (BMI) on subsequent response to subcutaneous (SC) abatacept in patients with psoriatic arthritis (PsA). METHODS: In ASTRAEA, patients with active...

Descripción completa

Detalles Bibliográficos
Autores principales: McInnes, Iain B, Ferraccioli, Gianfranco, D'Agostino, Maria-Antonietta, Le Bars, Manuela, Banerjee, Subhashis, Ahmad, Harris A, Elbez, Yedid, Mease, Philip J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560664/
https://www.ncbi.nlm.nih.gov/pubmed/31245054
http://dx.doi.org/10.1136/rmdopen-2019-000934

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560664/
https://www.ncbi.nlm.nih.gov/pubmed/31245054
http://dx.doi.org/10.1136/rmdopen-2019-000934

Ejemplares similares